Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Thomas Olencki"'
Autor:
Erin Jensen, Evan J Lipson, Martin A Cheever, Adil Daud, Brent A Hanks, Shailender Bhatia, Thomas Olencki, Kari Kendra, Mizuho Kalabis, William H Sharfman, Ragini R Kudchadkar, Philip A Friedlander, Sunil A Reddy, Brian C Boulmay, Adam Riker, Melissa A Burgess, Candice Church, Tomoko Akaike, Michi M Shinohara, Bob Salim, Blanca Homet Moreno
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with chemotherapy for MCC. The current stu
Externí odkaz:
https://doaj.org/article/73de26009f964e2780583bb59aad23b0
Autor:
Michael B. Atkins, David F. McDermott, David I. Quinn, Thomas Olencki, Thomas Hutson, Brian I. Rini, Laura S. Wood, Martin H. Voss, Hans Hammers, William Bro, Ronald M. Bukowski, Bernard Faba, Jo Faba, Robert A. Figlin, Eric Jonasch, Richard W. Joseph, Bradley C. Leibovich, Allan J. Pantuck, Virginia Seery, Christopher G. Wood
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted fo
Externí odkaz:
https://doaj.org/article/e2cf889874654be18d4dbbdd7a7a921c
Autor:
Michael A. Carducci, Richard Piekarz, Susan M. Perkins, Adrienne Groman, Alan Hutson, Zsolt Szabo, Roberto S. Fragomeni, Dominick Lamonica, Ashley Orillion, Li Shen, Thomas Olencki, Tanya B. Dorff, Saby George, Paul Monk, Hans J. Hammers, David I. Quinn, Roberto Pili
Supplemental Figure Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ecfbbe915ec46b5d85edbbc95635600
https://doi.org/10.1158/1078-0432.22466652
https://doi.org/10.1158/1078-0432.22466652
Autor:
William E. Carson, Michael Caligiuri, John C. Byrd, Susheela Tridandapani, Natarajan Muthusamy, Thomas Olencki, Nancy Stasik, Lianbo Yu, John Harrison Howard, Matthew Old, Robert Wesolowski, Megan Duggan, Vincent Hsu, Ian Landi, David Abood, Shalini Gautam, Amanda Campbell, Kari Kendra, Brooke Benner, Thomas A. Mace, Elizabeth McMichael, Bethany Mundy-Bosse, Prashant Trikha, Andrew Stiff
Supplemental Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51667ce655b4f091b7f7916826f47c36
https://doi.org/10.1158/1078-0432.22465190
https://doi.org/10.1158/1078-0432.22465190
Autor:
William E. Carson, Michael Caligiuri, John C. Byrd, Susheela Tridandapani, Natarajan Muthusamy, Thomas Olencki, Nancy Stasik, Lianbo Yu, John Harrison Howard, Matthew Old, Robert Wesolowski, Megan Duggan, Vincent Hsu, Ian Landi, David Abood, Shalini Gautam, Amanda Campbell, Kari Kendra, Brooke Benner, Thomas A. Mace, Elizabeth McMichael, Bethany Mundy-Bosse, Prashant Trikha, Andrew Stiff
Purpose: mAbs are used to treat solid and hematologic malignancies and work in part through Fc receptors (FcRs) on natural killer cells (NK). However, FcR-mediated functions of NK cells from patients with cancer are significantly impaired. Identifyin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e255333bc1b5264f55ecfef67062c6f
https://doi.org/10.1158/1078-0432.c.6525947.v1
https://doi.org/10.1158/1078-0432.c.6525947.v1
Autor:
William E. Carson, Stephen V. Liu, Michael A. Caligiuri, John C. Byrd, Susheela Tridandapani, Panos Savvides, Theodoros N. Teknos, Thomas Olencki, Bonnie Paul, Sarvani Uppati, Akaansha Ganju, Tiffany Noel, Gonzalo N. Olaverria Salavaggione, Kala Levine, Kyle Martin, Kallan Williams, Megan C. Duggan, Amanda R. Campbell, Melanie E. Davis, Xiaokui Mo, Nicholas B. Courtney, Lakhvir S. Atwal, Brooke Benner, Elizabeth L. McMichael
Supplemental Figure S1. Levels of serum cytokines in patients over the course of treatment. Serum levels of the cytokines IFN-γ (A), IP-10 (B), TNF-α (C) MIP-1α (D), MIP-1β (E), RANTES (F), GM CSF (G), and IL-8 (H) were measured at baseline and d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8119893f10dcaa84d086ec6e94a7d410
https://doi.org/10.1158/1078-0432.22473654.v1
https://doi.org/10.1158/1078-0432.22473654.v1
Autor:
William E. Carson, Stephen V. Liu, Michael A. Caligiuri, John C. Byrd, Susheela Tridandapani, Panos Savvides, Theodoros N. Teknos, Thomas Olencki, Bonnie Paul, Sarvani Uppati, Akaansha Ganju, Tiffany Noel, Gonzalo N. Olaverria Salavaggione, Kala Levine, Kyle Martin, Kallan Williams, Megan C. Duggan, Amanda R. Campbell, Melanie E. Davis, Xiaokui Mo, Nicholas B. Courtney, Lakhvir S. Atwal, Brooke Benner, Elizabeth L. McMichael
Supplemental Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b64ca0fa43e0f3983071c3c1c40f659
https://doi.org/10.1158/1078-0432.22473657.v1
https://doi.org/10.1158/1078-0432.22473657.v1
Autor:
William E. Carson, Michael Caligiuri, John C. Byrd, Susheela Tridandapani, Natarajan Muthusamy, Thomas Olencki, Nancy Stasik, Lianbo Yu, John Harrison Howard, Matthew Old, Robert Wesolowski, Megan Duggan, Vincent Hsu, Ian Landi, David Abood, Shalini Gautam, Amanda Campbell, Kari Kendra, Brooke Benner, Thomas A. Mace, Elizabeth McMichael, Bethany Mundy-Bosse, Prashant Trikha, Andrew Stiff
Supplemental Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::402f0d445e7ac25ef06082cc82ecaaa5
https://doi.org/10.1158/1078-0432.22465193.v1
https://doi.org/10.1158/1078-0432.22465193.v1
Autor:
Michael A. Carducci, Richard Piekarz, Susan M. Perkins, Adrienne Groman, Alan Hutson, Zsolt Szabo, Roberto S. Fragomeni, Dominick Lamonica, Ashley Orillion, Li Shen, Thomas Olencki, Tanya B. Dorff, Saby George, Paul Monk, Hans J. Hammers, David I. Quinn, Roberto Pili
Supplemental Figure 1. Tumor infiltrating Treg; Supplemental Figure 2. Treg and IFN�-CD8.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c13bec39fb77b6f5301f64a1f685aa83
https://doi.org/10.1158/1078-0432.22466649
https://doi.org/10.1158/1078-0432.22466649
Autor:
Michael A. Carducci, Richard Piekarz, Susan M. Perkins, Adrienne Groman, Alan Hutson, Zsolt Szabo, Roberto S. Fragomeni, Dominick Lamonica, Ashley Orillion, Li Shen, Thomas Olencki, Tanya B. Dorff, Saby George, Paul Monk, Hans J. Hammers, David I. Quinn, Roberto Pili
Purpose: On the basis of preclinical data suggesting that the class I selective HDAC inhibitor entinostat exerts a synergistic antitumor effect in combination with high-dose IL2 in a renal cell carcinoma model by downregulating Foxp3 expression and f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a1bd44f3c33ab401ae22560ef884451
https://doi.org/10.1158/1078-0432.c.6526389.v1
https://doi.org/10.1158/1078-0432.c.6526389.v1